Abstract

Background: Hip arthroplasty is a common surgical procedure effective for pain relief and maintaining walking function. Prosthetic joint infection (PJI) is a serious complication. Rifampicin combination therapy is widely used to treat PJIs caused by Staphylococcus aureus or coagulase-negative Staphylococcus, which are challenging to treat due to biofilm formation. However, its effectiveness is unclear. The effectiveness of anti-methicillin-resistant Staphylococcus aureus (MRSA) antibiotics combined with rifampicin is also unclear.
Objective: This study assessed the effectiveness and safety of MRSA antibiotics combined with rifampicin for treating methicillin-resistant staphylococcal PJI using a Japanese clinical database.
Materials and methods: This retrospective analysis used the claims database to examine data on PJI after hip arthroplasty among patients aged 20 years or older who were treated with anti-MRSA antibiotics, with or without rifampicin, from 2014 to 2021. The primary outcome was defined as no revision arthroplasty, while the safety outcomes were renal dysfunction and hypersensitivity.
Results: Among 52,588 patients who underwent hip replacement or artificial head insertion surgeries, 53 were treated for PJI with anti-MRSA antibiotics and received debridement, antibiotics, and implant retention, with 33 without rifampicin and 20 with rifampicin. The incidence of revision arthroplasty did not differ significantly between the two groups (3 vs. 5 patients; log-rank test, p = 0.195). The incidence of adverse events was similar between the two groups.
Conclusion: In this analysis, rifampicin combination therapy provided no additional benefit in treating methicillin-resistant PJI after hip replacement surgery. If used together, close monitoring for the occurrence of adverse effects is advised.

Author Details

Authors

• Ayaka Nitta^{1, 2}
• Mitsuhiro Goda^{1, 2}
• Takahiro Niimura^{1, 3}
• Toshiki Kajihara⁴
• Maki Sato¹
• Masayuki Chuma⁵
• Kei Kawada^{1, 6}
• Kaito Tsujinaka^{1, 2}
• Koji Miyata¹
• Yuki Kono¹
• Fuka Aizawa^{1, 2}
• Kenta Yagi^{1, 3}
• Yuki Izawa-Ishizawa^{1, 7}
• Keisuke Ishizawa^{1, 2, 3}

Departments

• ¹ Department of Clinical Pharmacology and Therapeutics, Tokushima University Graduate School of Biomedical Sciences,
• ² Department of Pharmacy,
• ³ Clinical Research Center for Developmental Therapeutics, Tokushima University Hospital, Tokushima,
• ⁴ Antimicrobial Resistance Research Center, National Institute of Infectious Diseases, Tokyo,
• ⁵ Department of Hospital Pharmacy and Pharmacology, Asahikawa Medical University, Asahikawa,
• ⁶ Department of Clinical Pharmacy Practice Pedagogy, Tokushima University Graduate School of Biomedical Sciences, and
• ⁷ Department of General Medicine, Taoka Hospital, Tokushima, Japan

Address

Mitsuhiro Goda, PhD
Department of Clinical Pharmacology and Therapeutics
Tokushima University Graduate School of Biomedical Sciences
3-18-15 Kuramoto, Tokushima 770-8503, Japan
Email: [email protected]

Citation